Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain MetastasesAnna Maria Di Giacomo, Michele Maio, Michele Guida et al.|Clinical Cancer Research|2021Cited by 75
1081MO Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trialAnna Maria Di Giacomo, Michele Maio, Michele Del Vecchio et al.|Annals of Oncology|2020Cited by 7